MedTrace Logo

Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme

NCT00921362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1387

Last updated 2009-06-16

No results posted yet for this study

Summary

Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms changes over 6 months in schizophrenia in patients treated with Seroquel; additionally disease severity and treatment compliance are followed

Conditions

Sponsors & Collaborators

Principal Investigators

  • stina Pentiuc, Med Director · AstraZeneca Romania

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00921362 on ClinicalTrials.gov